Tadalafil 20 mg to 40 mg Given Every Second Day Is Effective in Secondary Pulmonary Hypertensio

The most common adverse reaction is headache. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE1.1 Pulmonary Arterial Hypertension2 DOSAGE AND ADMINISTRATION2.1 Pulmonary Arterial Hypertension2.2 Dose Adjustment in Renal Impairment2.3 Dose Adjustment in Hepatic Impairment2.4 Dose Adjustment for Use with Ritonavir3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS4.1 Concomitant Organic Nitrates4.2 Concomitant Guanylate Cyclase (GC) Stimulators4.3 Hypersensitivity Reactions5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Visual Loss5.4 Hearing Impairment5.5 Combination with Other PDE5 Inhibitors5.6 Prolonged Erection6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 Nitrates7.2 Alpha-Blockers7.3 Antihypertensives7.4 Alcohol7.5 CYP3A Inhibitors/Inducers8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.3 Females and Males of Reproductive Potential8.4 Pediatric Use8.5 Geriatric Use8.6 Renal Impairment8.7 Hepatic Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2 Animal Toxicology and/or Pharmacology14 CLINICAL STUDIES14.1 Tadalafil tablets for Pulmonary Arterial Hypertension14.2 Long-Term Treatment of Pulmonary Arterial Hypertension16 HOW SUPPLIED/STORAGE AND HANDLING16.1 How Supplied16.2 Storage17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed. Sections or subsections omitted from the full prescribing information tadalafil 10mg daily are not listed.

• Do not take Tadalafil 40mg if you are on medications containing nitrates.
• Follow the prescribed dosing schedule strictly for safety and effectiveness.
• The medication may cause a sudden drop in blood pressure in some users.
• Inform your doctor about all health conditions before starting Tadalafil.
• Do not take more than one dose per day to avoid overdose risks.
• Use this medication responsibly to manage ED effectively and safely.

1 INDICATIONS AND USAGE 1.1 Pulmonary Arterial HypertensionTadalafil Tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Tadalafil Tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. 2 DOSAGE AND ADMINISTRATION 2.1 Pulmonary Arterial HypertensionThe recommended dose of tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food.

Pregnancy & Lactation

This drug occupies a leading position in the market for the treatment of erectile dysfunction. If you are not currently on any PAH therapy or are transitioning from an ERA alone: tadacip 20 mg tadalafil One OPSYNVI® pill (macitentan 10mg/tadalafil 20mg), once daily for 1 week. If tolerated, the doctor will increase your dose to one OPSYNVI® pill (macitentan 10mg/tadalafil 40mg), once daily. If you are transitioning from a PDE5i alone or taking the combination of an ERA and a PDE5i as individual pills: Start with one OPSYNVI® pill (macitentan 10mg/tadalafil 40mg), once daily. The pills illustrated above are not actual size.

QUALITATIVE AND QUANTITATIVE COMPOSITION:

Once you and your healthcare provider decide that OPSYNVI® is right for you, OPSYNVI® will be mailed to you by a specialty pharmacy. Take OPSYNVI® exactly as instructed by your healthcare provider. Do not stop taking OPSYNVI® unless your healthcare provider tells you to do so. OPSYNVI® is an oral pill of macitentan 10-mg/tadalfil 40-mg taken once daily by mouth. OPSYNVI® can be taken with or without food. Dividing the dose (40 mg) over the course of the day is not recommended.2.2 Dose Adjustment in Renal ImpairmentMild (creatinine clearance 51 mL/min to 80 mL/min) or moderate (creatinine clearance 31 mL/min to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.Severe (creatinine clearance less than 30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations (8.6)].2.3 Dose Adjustment in Hepatic ImpairmentMild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day.Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied.

Avoid use of tadalafil tablets [see Use in Specific Populations (8.7)].2.4 Dose Adjustment for Use with RitonavirCo-administration of tadalafil tablets in Patients on RitonavirIn patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily.

• Tadalafil 40mg is a potent PDE5 inhibitor used for specific medical needs.
• Check expiration date before using to ensure medication efficacy.
• Avoid taking Tadalafil 40mg with fatty meals if concerned about absorption.
• Lifestyle modifications can enhance the effectiveness of Tadalafil treatment.
• Combination therapy with other ED drugs is not usually recommended.
• Contact emergency services if you experience symptoms of a heart attack.

Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].Co-administration of Ritonavir in Patients on Tadalafil tabletsAvoid use of tadalafil tablets during the initiation of ritonavir.

Stop tadalafil tablets at least 24 hours prior to starting ritonavir.

Dosage Forms and Strengths of Tadalafil

Take the pill whole and do not cut, crush, or chew OPSYNVI® pills. If you accidentally take too much OPSYNVI®, contact your healthcare provider or go to the nearest hospital emergency room right away. If you miss a dose of OPSYNVI®, take it as soon as you remember that day. Take the next dose at your regular time. Do not take 2 doses at the same time to make up for a missed dose.

Tadalafil for Prostate Cancer

Download the OPSYNVI® brochure for quick access to the benefits and patient support options available to you. If you are a consumer or patient please visit this version. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS.TADALAFIL tablets, for oral useInitial U.S. Approval: 2003INDICATIONS AND USAGETadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily.

• Tadalafil 40mg is effective for both erectile dysfunction and BPH symptoms.
• It is important to hydrate well when using this medication.
• Avoid grapefruit or grapefruit juice when taking Tadalafil 40mg.
• Do not use Tadalafil 40mg if you are allergic to similar medications.
• Monitor blood pressure regularly during Tadalafil therapy.
• Side effects tend to be mild but consult a doctor if severe.

Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].

2. Strict Quality Control & Assurance

Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). (1.1)DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSTablets (not scored): 20 mg (3)CONTRAINDICATIONSWARNINGS AND PRECAUTIONSHypotension: Carefully consider whether patients with certain underlying cardiovascular disease could be adversely affected by vasodilatory effects of tadalafil. Not recommended in patients with pulmonary veno-occlusive disease. (5.1, 5.2)Effects on the eye: Sudden loss of vision could be a sign of non-arteritic ischemic optic neuropathy (NAION) and may be permanent. (5.3)Hearing impairment: Cases of sudden decrease or loss of hearing have been reported with CIALIS.

It changes more than your penis

(5.4)Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. (5.5)Prolonged erection: Advise patients to seek emergency treatment if an erection lasts greater than 4 hours. (5.6)ADVERSE REACTIONSThe most common adverse reaction is headache. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Ajanta Pharma 10 mg tadalafil USA Inc. at 1-855-664-7744 or FDA at 1-800-FDA-1088 or IN SPECIFIC POPULATIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 10/2025 Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. The recommended dose of tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food.

Dividing the dose (40 mg) over the course of the day is not recommended. Mild (creatinine clearance 51 mL/min to 80 mL/min) or moderate (creatinine clearance 31 mL/min to 50 mL/min): Start dosing at 20 mg once daily.

2.4 Dose Adjustment for Use with Ritonavir

24 participants in 2 patient groups, including a placebo group Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2. Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2. Tadalafil (Generic Tadafil) is a drug that is used to treat erectile dysfunction. It was developed in 1992 by ICI Pharmaceuticals. Tadalafil relaxes the smooth muscles in the cavernous body of the penis, which helps to increase blood flow and, as a result, the appearance of an erection.

Tadalafil for Coronary Artery Disease

More than 3,000 men participated in clinical trials of tadalafil. The results of the research have been published in several scientific publications in the USA. In particular, The Journal of Sexual Medicine published an article "The efficacy and safety of tadalafil in men with erectile dysfunction: a double-blind placebo-controlled phase 3 study". It provides data on the safety and effectiveness of tadalafil in the treatment of erectile dysfunction. According to data from scientific publications in the United States, in 2022, global sales of tadalafil amounted to more than $ 2.5 billion. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance less than 30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations (8.6)].

Medication savings with ScriptSave® WellRx

Hypotension: Carefully consider whether patients with certain underlying cardiovascular disease could be adversely affected by vasodilatory effects of tadalafil. Effects on the eye: Sudden loss of vision could be a sign of non-arteritic ischemic optic neuropathy (NAION) and may be permanent. Hearing impairment: Cases of sudden decrease or loss of hearing have been reported with CIALIS. Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. Prolonged erection: Advise patients to seek emergency treatment if an erection lasts greater than 4 hours.